Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze the...
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions01:24

Drug Accumulation During Multiple Dosing: Intermittent IV Infusions

Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
Desensitization and Tachyphylaxis01:20

Desensitization and Tachyphylaxis

Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
Several...
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
GPCR Desensitization01:12

GPCR Desensitization

G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An anti-PMEL antibody-drug conjugate with a G<sub>q/1</sub><sub>1</sub> inhibitor payload in GNAQ/GNA11-mutant melanomas: a phase 1 trial.

Nature medicine·2026
Same author

Liquid Biopsy in Cutaneous Oncology: Current Practice and Future Directions.

Journal of the American Academy of Dermatology·2026
Same author

Chick welfare in a large, commercial chicken hatchery: A case study.

Open veterinary journal·2026
Same author

Personalized targeting of BCL2 family proteins overcomes acquired resistance to BRAF-MEK inhibitors in preclinical melanoma.

Nature communications·2026
Same author

Immune checkpoint inhibitor therapy after tumor-infiltrating lymphocytes in unresectable melanoma.

Journal for immunotherapy of cancer·2026
Same author

Multimodal blood based proteomic profiling reveals insights into mechanisms of immunotherapy resistance.

Nature communications·2026

Related Experiment Video

Updated: May 11, 2026

A Method for Evaluating Timeliness and Accuracy of Volitional Motor Responses to Vibrotactile Stimuli
07:28

A Method for Evaluating Timeliness and Accuracy of Volitional Motor Responses to Vibrotactile Stimuli

Published on: August 2, 2016

Beyond empiric checkpoint escalation: Insights from KEYVIBE-010.

Andrew Knight1, Ryan J Sullivan2

  • 1Mass General Brigham Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Dana Farber Cancer Institute, Boston, MA, USA.

Med (New York, N.Y.)
|May 9, 2026
PubMed
Summary

The KEYVIBE-010 trial found that combining adjuvant vibostolimab and pembrolizumab did not improve efficacy in high-risk melanoma patients and increased toxicity. This suggests limited benefit for dual checkpoint inhibition in this setting.

More Related Videos

Temporal Tracking of Cell Cycle Progression Using Flow Cytometry without the Need for Synchronization
08:52

Temporal Tracking of Cell Cycle Progression Using Flow Cytometry without the Need for Synchronization

Published on: August 16, 2015

Developing Custom Chinese Hamster Ovary-host Cell Protein Assays using Acoustic Membrane Microparticle Technology
07:13

Developing Custom Chinese Hamster Ovary-host Cell Protein Assays using Acoustic Membrane Microparticle Technology

Published on: February 3, 2011

Related Experiment Videos

Last Updated: May 11, 2026

A Method for Evaluating Timeliness and Accuracy of Volitional Motor Responses to Vibrotactile Stimuli
07:28

A Method for Evaluating Timeliness and Accuracy of Volitional Motor Responses to Vibrotactile Stimuli

Published on: August 2, 2016

Temporal Tracking of Cell Cycle Progression Using Flow Cytometry without the Need for Synchronization
08:52

Temporal Tracking of Cell Cycle Progression Using Flow Cytometry without the Need for Synchronization

Published on: August 16, 2015

Developing Custom Chinese Hamster Ovary-host Cell Protein Assays using Acoustic Membrane Microparticle Technology
07:13

Developing Custom Chinese Hamster Ovary-host Cell Protein Assays using Acoustic Membrane Microparticle Technology

Published on: February 3, 2011

Area of Science:

  • Oncology
  • Immunotherapy
  • Clinical Trials

Background:

  • Adjuvant therapy is crucial for resected, high-risk melanoma to prevent recurrence.
  • Immune checkpoint inhibitors (ICIs) like pembrolizumab have improved outcomes in melanoma.
  • Combined ICI strategies are being explored to enhance efficacy.

Purpose of the Study:

  • To evaluate the efficacy and safety of adjuvant vibostolimab plus pembrolizumab versus pembrolizumab monotherapy in high-risk melanoma.
  • To determine if combination ICI therapy offers improved disease-free survival in the adjuvant setting.

Main Methods:

  • Phase 3, randomized clinical trial (KEYVIBE-010).
  • Patients with resected, high-risk melanoma were randomized to receive either combination ICI or pembrolizumab monotherapy.
  • Trial was stopped early due to futility.

Main Results:

  • The combination of vibostolimab and pembrolizumab demonstrated higher toxicity compared to pembrolizumab monotherapy.
  • No significant improvement in efficacy was observed with the combination therapy.
  • The trial was terminated prematurely due to lack of benefit and increased adverse events.

Conclusions:

  • Combined adjuvant vibostolimab and pembrolizumab is not superior to pembrolizumab monotherapy for high-risk melanoma.
  • The current data suggest a limited role for dual checkpoint inhibition in the adjuvant treatment of resected, high-risk melanoma.
  • Vigilant monitoring for toxicity is essential when considering combination immunotherapy strategies.